University of Sydney

sydney.edu.au

Total trials

93

Active

31

Phase 3

18

Total enrollment

76,220

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 28 of 28 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
N-acetyl cysteine1
Enzalutamide2
Methylprednisolone1
Prednisone1
Vitamin K11
Magnesium citrate1
Sodium Thiosulfate1
Darolutamide1
Luteinizing Hormone-Releasing Hormone Analog1
Conventional NSAA1
LHRHA1
Bleomycin1
Etoposide1
Cisplatin1
Pegylated G-CSF1
Filgrastim1
Fosfomycin1
Standard of care antibiotics1
Fenofibrate1
Inert lactose placebo1
NSAA1
LHRHA or Surgical Castration1
Tenecteplase1
Niacin2
Psilocybin1
MDMA1
Nivolumab1
Temozolomide1

Next readouts

  • 2024-06-28
  • 2024-12-31
  • 2025-07
  • 2025-11
  • 2026-05
  • 2026-06
  • 2026-08-28
  • 2026-12-31
  • 2027-08
  • 2028-01-31

Top conditions

  • Lung Cancer5
  • Diabetic Macular Oedema5
  • Cancer4
  • Diabetic Retinopathy4
  • Obesity4
  • Stroke3
  • Prostate Cancer2
  • Alcohol Use Disorder2

Frequently asked questions about University of Sydney

How many clinical trials does University of Sydney have on ClinicalTrials.gov?
University of Sydney is listed as the lead sponsor on 93 clinical trials in ClinicalTrials.gov, 31 of which are currently active (recruiting, enrolling, or ongoing).
How many of University of Sydney's trials are in Phase 3?
18 of University of Sydney's trials are in Phase 3, spread across 28 active drug programs.
What therapeutic areas does University of Sydney focus on?
University of Sydney's most-studied conditions on ClinicalTrials.gov are Lung Cancer, Diabetic Macular Oedema, Cancer, Diabetic Retinopathy, Obesity.
When are University of Sydney's next clinical trial readouts?
University of Sydney has 10 upcoming primary-completion readouts tracked here; the soonest is “Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM”, expected around 2024-06-28.